Eleusis Presents New Research on the Anti-Inflammatory Potential of Serotonin _2A Receptor Agonists at the 2019 International Society for Research on Psychedelics

Eleusis, a clinical stage life science company established to develop the therapeutic potential of serotonin _2A receptor (5-HT_2A) agonists, also known as psychedelics, today announced new research presented at the inaugural 2019 International Society for Research on Psychedelics (ISRP) conference held October 18-20, in New Orleans, U.S. In both oral platform presentations and posters, Eleusis data demonstrated preclinical efficacy of topically administered serotonin _2A receptor agonists in viral, allergen, and antigen induced ocular inflammation, via translational models of herpes keratitis, allergic conjunctivitis, uveitis, and diabetic macular edema. In addition, Eleusis sponsored researchers also presented on the anti-inflammatory potential of serotonin _2A agonists in translational models of asthma, cardiovascular disease, and for the first time, revealed new findings that suggest a potent anti-fibrotic effect of serotonin _2A agonists in vitro, consistent with previously disclosed effects against pulmonary fibrosis.

“We are excited to present these new findings at the inaugural ISRP meeting, and believe they expand the scientific community’s appreciation for the full potential of psychedelics as sub-perceptual medicines,” said Shlomi Raz, Chairman and Founder of Eleusis. “The findings presented further demonstrate the anti-inflammatory capacity of serotonin 5-HT_2A receptor agonists, and specifically, their potential to treat ocular inflammation and prevent retinal degeneration.”

Eleusis Presentation Details

Oral Presentations

Session Title: Anti-Inflammatory Effects of Psychedelics

• 5-HT_2A Receptor Agonists as Anti-Inflammatory Therapeutics

• Structure Activity of 5-HT_2A Receptor Agonists for Anti-Inflammatory Properties In Vivo

• Interactions Between 5-HT_2A Receptor and EGF Receptor Signaling Modulate EGF-Induced Vascular Inflammation

• Pathogen-Induced Serotonin Production Correlates with Severity of Inflammation-Associated Disease

Poster Session

• Anti-Inflammatory and Protective Effects of Topical Ophthalmic (R)-DOI 0.01% in Allergic Conjunctivitis and Recurrent Intermediate Uveitis Models in Rabbits

• Selective Agonism of the 5-HT_2A Receptor Suppresses Profibrotic Gene Expression and Fibrobrast to Myofibroblasts Trans-differentiation

About Eleusis Ltd.

Founded in 2013, Eleusis is the first privately held, clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design. The company’s comprehensive discovery, development and delivery capabilities enable it to target a broad spectrum of unmet needs within psychiatry, and beyond psychiatry. For more information, visit https://www.eleusisltd.com/

Contacts:

Eleusis Inquiries:

Alex Speiser
Email: alexander.speiser@eleusisltd.com

Media:

Dan Gagnier / Jeffrey Mathews
Tel: 646-569-5897
Email: eleusis@gagnierfc.com